Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8506 to 8520 of 8887 results

  1. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  3. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  5. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued Reference number: GID-TA10325

    Technology appraisal guidance
    Discontinued

  6. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued

  7. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued Reference number: GID-TA10512

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued Reference number: GID-TA10567

    Technology appraisal guidance
    Discontinued

  10. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  11. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  13. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued Reference number: GID-TA10221

    Technology appraisal guidance
    Discontinued

  15. Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

    In development Reference number: GID-TA10391 Expected publication date: TBC

    Technology appraisal guidance
    In development